Trinity Biotech (NASDAQ:TRIB) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report issued on Saturday. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Down 7.8 %

TRIB stock opened at $2.82 on Friday. The stock’s 50 day moving average is $2.13 and its two-hundred day moving average is $2.17. Trinity Biotech has a 52-week low of $1.49 and a 52-week high of $5.25. The company has a market capitalization of $21.49 million, a PE ratio of -1.01 and a beta of 1.31.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. The firm had revenue of $14.70 million for the quarter. As a group, sell-side analysts anticipate that Trinity Biotech will post -2.17 EPS for the current year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.